<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783289</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP197</org_study_id>
    <nct_id>NCT00783289</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple-dose Subcutaneous Administration of MEDI-563, a Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of escalating
      multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, randomized, double-blind, placebo-controlled, dose-escalation,
      multicenter study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity
      of multiple subcutaneous doses (25, 100, or 200 milligram [mg]) of benralizumab (MEDI-563) in
      adult subjects with asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2008</start_date>
  <completion_date type="Actual">November 17, 2009</completion_date>
  <primary_completion_date type="Actual">November 17, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Day 0 to Day 161</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab</measure>
    <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for Benralizumab</measure>
    <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab</measure>
    <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
    <description>Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-Life (t1/2) for Benralizumab</measure>
    <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
    <description>Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit</measure>
    <time_frame>Day 0, 28, 56, 84, 112, and 161</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab 25 mg</intervention_name>
    <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
    <arm_group_label>Benralizumab 25 mg</arm_group_label>
    <other_name>MEDI-563</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab 100 mg</intervention_name>
    <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
    <arm_group_label>Benralizumab 100 mg</arm_group_label>
    <other_name>MEDI-563</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab 200 mg</intervention_name>
    <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
    <arm_group_label>Benralizumab 200 mg</arm_group_label>
    <other_name>MEDI-563</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects

          -  Age 18 through 80 years at screening

          -  Written informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization obtained from the subject prior to performing any
             protocol-related procedures, including screening evaluations

          -  Previously documented diagnosis of asthma of more than or equal to (&gt;=) 1 year
             duration, based on episodic symptoms of airflow obstruction; post-bronchodilator
             reversibility of airflow obstruction &gt;=12 percent (%) (at screening or documented
             within 1 year prior to randomization); or proof of a positive response to a
             methacholine challenge (documented within 1 year prior to randomization) as
             represented by a provoking concentration of methacholine to cause a 20% fall in forced
             expiratory volume in 1 second (FEV1); (PC20) less than (&lt;) 8 milligram per milliliter
             (mg/mL)

          -  Weight of &gt;=45 kilogram (kg) but less than or equal to (&lt;=) 135 kg (&gt;=100 pounds [lb]
             but &lt;=300 lb)

          -  Able to produce spirometry readings that meet American Thoracic Society (ATS)/European
             Respiratory Society (ERS) standards

          -  Screening pre-bronchodilator FEV1 &gt;=60%

          -  Women of childbearing potential, unless surgically sterile (including tubal ligation)
             and/or at least 2 years post-menopausal, must use 2 effective methods of avoiding
             pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine
             device, female condom with spermicide, diaphragm with spermicide, cervical cap,
             abstinence, use of a condom with spermicide by the sexual partner, or sterile sexual
             partner) for 14 days prior to the first dose of the investigational product on Study
             Day 0, and must agree to continue using such precautions through Study Day 161.
             Cessation of birth control after this point should be discussed with a responsible
             physician

          -  Men, unless surgically sterile, must likewise use 2 effective methods of birth control
             (for example, condom with spermicide) and must agree to continue using such
             contraceptive precautions through End of Study/Study Day 161

          -  Ability to complete the study period, including follow-up period until Study Day 161
             as required by protocol

        Exclusion Criteria:

          -  Previously received benralizumab (MEDI-563)

          -  History of allergy or reaction to any component of the investigational product
             formulation

          -  History of allergy or reaction to any other marketed or experimental monoclonal
             antibody therapies, intravenous gammaglobulin (IVIG), or blood products

          -  Receipt of any investigational drug therapy within 30 days prior to randomization into
             the study or any biologic(s) within 5 half-lives of the agent prior to randomization
             into the study

          -  Treatment with an oral or systemic burst of corticosteroids within 4 weeks prior to
             randomization into the study

          -  Use of any chronic systemic immunosuppressive drugs, including oral corticosteroids
             within 4 weeks prior to randomization into the study

          -  Current use of any oral or ophthalmic beta-adrenergic antagonist (for example,
             propranolol), must have been stopped 2 weeks prior to randomization into the study

          -  Current allergy vaccination (immunotherapy)

          -  History of anaphylaxis

          -  Lung disease other than persistent asthma (for example, chronic bronchitis, cystic
             fibrosis, chronic obstructive pulmonary disease [COPD], tuberculosis [TB])

          -  Acute illnesses or evidence of significant active infection, such as fever &gt;=38.0
             degrees Celsius [C] (&gt;=100.5 degrees Fahrenheit [F]) at screening and up through time
             of the first dose of the investigational product

          -  History of ingestion of untreated water in a location known to be infected with
             parasites, resulting in acute or chronic diarrhea; or an untreated parasitic infection
             within 1 month of randomization

          -  Pregnancy (women of childbearing potential must have a negative serum pregnancy test
             at screening and a negative urine pregnancy test prior to administration of the
             investigational product)

          -  Lactating woman

          -  Infection with human immunodeficiency virus (HIV)-1, HIV-2, or hepatitis A, B, or C
             virus

          -  History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix
             treated with apparent success with curative therapy &gt;= 1 year prior to randomization
             into the study

          -  History of cigarette smoking &gt;=10 pack years

          -  History of alcohol abuse or drug abuse that required treatment &lt;1 year prior to
             randomization into the study

          -  Elective surgery planned during the study period

          -  Evidence of any systemic disease or any finding upon physical examination, laboratory
             abnormality, chest x-ray (CXR), or electrocardiogram (ECG) that, in the opinion of the
             investigator or medical monitor, may compromise the safety of the subject in the study
             or confound the analysis of the study results

          -  Employees of the clinical study site or any other individuals involved with the
             conduct of the study, or first degree family members of such individuals (that is,
             parents, siblings, or children)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gossage, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=64</url>
    <description>Attachments tab: MI-CP197 Redacted Protocol_22_Jul_2015</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>December 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 27, 2019</results_first_posted>
  <disposition_first_submitted>June 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 29, 2012</disposition_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Benralizumab</keyword>
  <keyword>MEDI-563</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="P2">
          <title>Benralizumab 25 mg</title>
          <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="P3">
          <title>Benralizumab 100 mg</title>
          <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="P4">
          <title>Benralizumab 200 mg</title>
          <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all participants randomized into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="B2">
          <title>Benralizumab 25 mg</title>
          <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="B3">
          <title>Benralizumab 100 mg</title>
          <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="B4">
          <title>Benralizumab 200 mg</title>
          <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="11.2"/>
                    <measurement group_id="B2" value="50.4" spread="12.3"/>
                    <measurement group_id="B3" value="45.5" spread="13.4"/>
                    <measurement group_id="B4" value="40.2" spread="12.5"/>
                    <measurement group_id="B5" value="45.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Day 0 to Day 161</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 25 mg</title>
            <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Benralizumab 200 mg</title>
            <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab</title>
        <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 25 mg</title>
            <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 200 mg</title>
            <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab</title>
          <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="7.00" upper_limit="28.00"/>
                    <measurement group_id="O2" value="7.00" lower_limit="1.00" upper_limit="7.00"/>
                    <measurement group_id="O3" value="7.00" lower_limit="7.00" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for Benralizumab</title>
        <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 25 mg</title>
            <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 200 mg</title>
            <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for Benralizumab</title>
          <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.152" spread="0.615" lower_limit="7" upper_limit="28"/>
                    <measurement group_id="O2" value="4.127" spread="1.775" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O3" value="15.637" spread="8.062" lower_limit="7" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab</title>
        <description>Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.</description>
        <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 25 mg</title>
            <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 200 mg</title>
            <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab</title>
          <description>Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>microgram*day per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.335" spread="69.640" lower_limit="7" upper_limit="28"/>
                    <measurement group_id="O2" value="405.868" spread="205.856" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O3" value="1157.013" spread="86.444" lower_limit="7" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Elimination Half-Life (t1/2) for Benralizumab</title>
        <description>Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.</description>
        <time_frame>Day 0, 1, 7, 28, 35, 56, 84, 112, and 161</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 25 mg</title>
            <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 200 mg</title>
            <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half-Life (t1/2) for Benralizumab</title>
          <description>Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational product. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.163" spread="2.368" lower_limit="7" upper_limit="28"/>
                    <measurement group_id="O2" value="18.610" spread="3.905" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O3" value="18.315" spread="3.484" lower_limit="7" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit</title>
        <time_frame>Day 0, 28, 56, 84, 112, and 161</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 25 mg</title>
            <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Benralizumab 100 mg</title>
            <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Benralizumab 200 mg</title>
            <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit</title>
          <population>Safety population included all participants who received at least 1 dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Day 161</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="E2">
          <title>Benralizumab 25 mg</title>
          <description>Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="E3">
          <title>Benralizumab 100 mg</title>
          <description>Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.</description>
        </group>
        <group group_id="E4">
          <title>Benralizumab 200 mg</title>
          <description>Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Troponin i increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rene van der Merwe, MBChB/Senior Director, Clinical Development</name_or_title>
      <organization>MedImmune, LLC.</organization>
      <phone>301-398-0000</phone>
      <email>vandermerwer@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

